Converge Bio

ConvergeAB™ designs and optimizes antibodies for selection, lead optimization, and de novo generation across IgG, VHH, scFv, and bispecifics, ranked by binding and developability.

Category: SaaS
Funding: VC-backed

Every fact above is shown only where it could be checked against a source: funding against a primary source, backers against the investor’s own directory, and a location only where the company names that city on its own site. A row that is absent is one we could not source, not a zero. The summary is the company’s own current wording. Category is our own classification. Spotted something wrong? Tell us.

Frequently asked questions

What does Converge Bio do?

ConvergeAB™ designs and optimizes antibodies for selection, lead optimization, and de novo generation across IgG, VHH, scFv, and bispecifics, ranked by binding and developability.

Where is Converge Bio based?

Location for Converge Bio has not been disclosed publicly.

How much has Converge Bio raised?

Converge Bio is vc-backed. Funding details have not been disclosed.